Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
vasopharm GmbH, a private biopharmaceutical company developing a novel treatment for traumatic brain injury, announced the successful completion of a €9.5 million financing co-led by HeidelbergCapital Private Equity and EF Investments.
BioArctic received MEUR 15 milestone payment from Eisai for start of BAN2401 confirmatory Phase 3 study in early Alzheimer’s disease
Allergy Therapeutics plc provides a trading update for the year ended 30 June 2019 ahead of its Preliminary Results to be announced on 25 September 2019.
Heidelberg Pharma AG published its financial report on the first six months of 2019
Expedeon AG announced that the Annual General Meeting held in Heidelberg yesterday, July 09, 2019, approved all management proposals.
Global, unaudited sales of HEMOBLAST™ Bellows for the first half of 2019 were €1.4 million – on track to achieve 2019 revenue guidance range of €4.0-4.5 million; projection for 15% market share in the US and main European countries remains a long-term goal
As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
Nephros, Inc., a commercial-stage company that develops and sells high performance water purification products to the medical device and commercial markets, announced preliminary financial results for the quarter ended June 30, 2019.
Inspire Medical Systems, Inc., a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced that it will release financial results for the second quarter 2019 after the close of trading on Tuesday, August 6.
Global Blood Therapeutics, Inc. announced that on July 1, 2019, the compensation committee of GBT’s board of directors granted 13 new employees options to purchase an aggregate of 4,000 shares of the company’s common stock with a per share exercise price of $53.93 and restricted stock units for an aggregate of 31,700 shares of the company’s common stock.